Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
Treatment of HER2-positive early breast cancer (EBC) continues to evolve with neoadjuvant (pre-operative) and adjuvant (post-operative) HER2-targeted therapies as standard of care. There are two important decision points. The first involves deciding between neoadjuvant therapy or proceeding directly...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
20 May 2021
|
| In: |
Cancer treatment reviews
Year: 2021, Jahrgang: 99, Pages: 1-11 |
| ISSN: | 1532-1967 |
| DOI: | 10.1016/j.ctrv.2021.102229 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ctrv.2021.102229 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0305737221000773 
|
| Verfasserangaben: | Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1775657434 | ||
| 003 | DE-627 | ||
| 005 | 20240414193527.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211028s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ctrv.2021.102229 |2 doi | |
| 035 | |a (DE-627)1775657434 | ||
| 035 | |a (DE-599)KXP1775657434 | ||
| 035 | |a (OCoLC)1341422428 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Jackisch, Christian |d 1960- |e VerfasserIn |0 (DE-588)1024193160 |0 (DE-627)71932730X |0 (DE-576)368124908 |4 aut | |
| 245 | 1 | 0 | |a Risk-based decision-making in the treatment of HER2-positive early breast cancer |b Recommendations based on the current state of knowledge |c Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart |
| 264 | 1 | |c 20 May 2021 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.10.2021 | ||
| 520 | |a Treatment of HER2-positive early breast cancer (EBC) continues to evolve with neoadjuvant (pre-operative) and adjuvant (post-operative) HER2-targeted therapies as standard of care. There are two important decision points. The first involves deciding between neoadjuvant therapy or proceeding directly to surgery. Neoadjuvant chemotherapy (NACT) plus pertuzumab-trastuzumab is appropriate for patients with high-risk HER2-positive EBC (tumour diameter ≥2 cm, and/or node-positive disease). Patients with node-negative disease and tumour diameter <2 cm are candidates for upfront surgery followed by paclitaxel for 12 weeks plus 18 cycles of trastuzumab, with the option to add pertuzumab (if pN+). The second decision point involves the pathohistological result at surgery after neoadjuvant therapy. Total pathological complete response (tpCR: ypT0/is, ypN0) is associated with improved survival endpoints. Patients with tumours ≥2 cm and/or node-positive disease at diagnosis who have a tpCR after dual blockade should continue pertuzumab-trastuzumab in the adjuvant setting to complete 1 year (18cycles) of treatment. For patients with invasive residual disease, 14cycles of post-neoadjuvant trastuzumab emtansine (T-DM1) therapy significantly increases invasive-DFS compared with trastuzumab. Extended adjuvant therapy with neratinib is an option in selected patients (HER2-positive and oestrogen receptor [ER]-positive) who have completed adjuvant trastuzumab-based therapy. Less aggressive chemotherapy regimens are recommended in populations with a lower risk of recurrence (patients with small tumours without axillary involvement; patients unlikely to tolerate anthracycline-taxane or taxane-carboplatin regimens). Ultimately, treatment recommendations should be consistent with local and international guidelines. Further studies will guide optimisation of treatment for patients with HER2-positive EBC according to the risk of disease recurrence. | ||
| 650 | 4 | |a HER2-postive early breast cancer | |
| 650 | 4 | |a Neoadjuvant therapy | |
| 650 | 4 | |a Neratinib | |
| 650 | 4 | |a Pertuzumab | |
| 650 | 4 | |a T-DM1 | |
| 650 | 4 | |a Trastuzumab | |
| 700 | 1 | |a Cortazar, Patricia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geyer, Charles E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gianni, Luca |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gligorov, Joseph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Machackova, Zuzana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perez, Edith A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Tolaney, Sara M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Untch, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wardley, Andrew |e VerfasserIn |4 aut | |
| 700 | 1 | |a Piccart, Martine |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer treatment reviews |d Amsterdam [u.a.] : Elsevier, 1974 |g 99(2021), Artikel-ID 102229, Seite 1-11 |h Online-Ressource |w (DE-627)320417158 |w (DE-600)2002084-3 |w (DE-576)104194154 |x 1532-1967 |7 nnas |a Risk-based decision-making in the treatment of HER2-positive early breast cancer Recommendations based on the current state of knowledge |
| 773 | 1 | 8 | |g volume:99 |g year:2021 |g elocationid:102229 |g pages:1-11 |g extent:11 |a Risk-based decision-making in the treatment of HER2-positive early breast cancer Recommendations based on the current state of knowledge |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ctrv.2021.102229 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0305737221000773 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211028 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 8 | ||
| 999 | |a KXP-PPN1775657434 |e 3997051909 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Christian Jackisch, Patricia Cortazar, Charles E. Geyer, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart"]},"language":["eng"],"note":["Gesehen am 28.10.2021"],"recId":"1775657434","person":[{"given":"Christian","display":"Jackisch, Christian","family":"Jackisch","role":"aut"},{"given":"Patricia","display":"Cortazar, Patricia","role":"aut","family":"Cortazar"},{"role":"aut","family":"Geyer","given":"Charles E.","display":"Geyer, Charles E."},{"given":"Luca","display":"Gianni, Luca","family":"Gianni","role":"aut"},{"family":"Gligorov","role":"aut","given":"Joseph","display":"Gligorov, Joseph"},{"family":"Machackova","role":"aut","given":"Zuzana","display":"Machackova, Zuzana"},{"role":"aut","family":"Perez","given":"Edith A.","display":"Perez, Edith A."},{"display":"Schneeweiss, Andreas","given":"Andreas","family":"Schneeweiss","role":"aut"},{"role":"aut","family":"Tolaney","given":"Sara M.","display":"Tolaney, Sara M."},{"given":"Michael","display":"Untch, Michael","family":"Untch","role":"aut"},{"display":"Wardley, Andrew","given":"Andrew","family":"Wardley","role":"aut"},{"display":"Piccart, Martine","given":"Martine","role":"aut","family":"Piccart"}],"id":{"doi":["10.1016/j.ctrv.2021.102229"],"eki":["1775657434"]},"physDesc":[{"extent":"11 S."}],"title":[{"title_sort":"Risk-based decision-making in the treatment of HER2-positive early breast cancer","subtitle":"Recommendations based on the current state of knowledge","title":"Risk-based decision-making in the treatment of HER2-positive early breast cancer"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"20 May 2021","dateIssuedKey":"2021"}],"relHost":[{"id":{"zdb":["2002084-3"],"issn":["1532-1967"],"eki":["320417158"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Cancer treatment reviews","title_sort":"Cancer treatment reviews"}],"origin":[{"dateIssuedKey":"1974","publisherPlace":"Amsterdam [u.a.] ; Burlington, Mass.","publisher":"Elsevier ; Harcourt","dateIssuedDisp":"1974-"}],"recId":"320417158","disp":"Risk-based decision-making in the treatment of HER2-positive early breast cancer Recommendations based on the current state of knowledgeCancer treatment reviews","type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"volume":"99","year":"2021","text":"99(2021), Artikel-ID 102229, Seite 1-11","pages":"1-11","extent":"11"},"language":["eng"],"pubHistory":["1.1974 -"],"note":["Gesehen am 22.01.2020"]}]} | ||
| SRT | |a JACKISCHCHRISKBASEDD2020 | ||